18 October 2019 -  Eight agenda items; not one new medicine/product.

The PTAC is set to consider the following medicines:

• Multiple (listed) medicines for multiple sclerosis - widening access criteria (nothing new here) 
• Cladribine - multiple sclerosis  (new use for an old medicine)
• Sirolimus - widening of access to include lymphovascular malformations (new use for an old medicine)
• mTOR inhibitors - renal angiomyolipoma and refractory seizures associated with tuberous sclerosis complex (nothing new here)
• TNF alfa inhibitors - amendment of criteria for juvenile idiopathic arthritis (nothing new here)
• Tacrolimus suppository – rectal inflammation (new formulation of an old medicine)
• Adalimumab & infliximab - drug monitoring Inflammatory bowel disease (nothing new here)
• Adalimumab - ulcerative colitis (new use for an old medicine)

Read PTAC agenda